Rani Therapeutics (NASDAQ:RANI) Earns Buy Rating from Analysts at Rodman & Renshaw
Rodman & Renshaw began coverage on shares of Rani Therapeutics (NASDAQ:RANI – Free Report) in a research report released on Thursday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $10.00 target price on the stock. RANI has been the subject of a number of other reports. HC Wainwright lifted their price target […]
More Stories
Head to Head Analysis: U Power (NASDAQ:UCAR) & Dorman Products (NASDAQ:DORM)
U Power (NASDAQ:UCAR – Get Free Report) and Dorman Products (NASDAQ:DORM – Get Free Report) are both auto/tires/trucks companies, but...
Village Farms International, Inc. (TSE:VFF) Director Buys C$12,552.30 in Stock
Village Farms International, Inc. (TSE:VFF – Get Free Report) Director Stephen Ruffini bought 10,000 shares of the firm’s stock in...
Jaguar Mining Inc. (TSE:JAG) Senior Officer Sells C$11,280.00 in Stock
Jaguar Mining Inc. (TSE:JAG – Get Free Report) Senior Officer Jonathan Victor Hill sold 2,000 shares of the firm’s stock...
Able View Global Inc. (NASDAQ:ABLV) Sees Significant Decline in Short Interest
Able View Global Inc. (NASDAQ:ABLV – Get Free Report) saw a significant decline in short interest in the month of...
Analysts Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $33.67
enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) has been assigned an average recommendation of “Buy” from the seven analysts...
Brokerages Set Rubrik, Inc. (NYSE:RBRK) PT at $44.69
Rubrik, Inc. (NYSE:RBRK – Get Free Report) has earned a consensus recommendation of “Buy” from the seventeen brokerages that are...